Topical anti-inflammatory pharmacology for atopic + inflammatory skin diseases (atopic dermatitis, psoriasis, contact dermatitis, lichen, vitiligo). Three primary mechanistic classes: (1) Topical corticosteroids (TCS) — GR agonists with potency stratified by class (super-potent class I clobetasol → class VII low-potency hydrocortisone-topical). GR → transrepression of NF-κB target cytokines + induction of anti-inflammatory genes (lipocortin-1, IκBα). Side effects: skin atrophy, striae, telangiectasia, HPA suppression with prolonged + high-potency use; tachyphylaxis. (2) Topical calcineurin inhibitors (TCI) — tacrolimus-topical 0.03/0.1%, pimecrolimus 1%. FKBP12-calcineurin complex blocks NFAT → ↓IL-2 + ↓IL-4 + ↓IL-13. Steroid-sparing alternative, especially in atopic dermatitis on face/folds. Original FDA boxed warning for theoretical malignancy risk has eased. (3) PDE4 inhibitors — crisaborole 2% — cAMP elevation → ↓pro-inflammatory cytokines. Steroid-sparing, mild atopic dermatitis. (4) Topical JAK inhibitors — ruxolitinib-topical (Opzelura, atopic dermatitis + vitiligo) — JAK1/2 inhibition → ↓IFN + IL-4 + IL-13 signaling. Strategy: highest-potency steroid burst → step-down → maintenance with steroid-sparing TCI / PDE4 / JAKi to avoid TCS adverse effects. Cross-links: glucocorticoid receptor signaling (TCS mechanism), calcineurin nfat t cell activation (TCI mechanism), jak stat signaling (JAKi), asthma th2 eosinophil inflammation (atopic march).
Organ Systems
integumentary
immune-hematologic
Pathway Steps
skin barrier dysfunction (filaggrin LOF, scratch-itch cycle) → epidermal cytokine release + Th2 polarization — via atopic dermatitis pathogenesis substrate. Inflammatory skin disease like atopic dermatitis starts with barrier dysfunction (often filaggrin loss-of-function) that admits allergens/irritants and, with the itch-scratch cycle, triggers keratinocyte alarmins and a Th2-skewed response. Treating barrier and inflammation together is the basis of modern AD management.
topical corticosteroid + GR → GR-cytoplasmic → nuclear translocation — via transrepression of NF-κB targets + transactivation of anti-inflammatory genes. Topical corticosteroids bind the cytoplasmic glucocorticoid receptor, which sheds chaperones and enters the nucleus to induce anti-inflammatory genes and (by tethering) repress NF-κB/AP-1-driven inflammatory genes. This broad transcriptional action is why TCS remain first-line, ranked by potency for site and severity.
topical calcineurin inhibitor + FKBP12 → calcineurin block → ↓NFAT — via ↓IL-2 + ↓IL-4 + ↓IL-13 in skin T cells. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) bind FKBP12; the complex inhibits calcineurin, blocking NFAT dephosphorylation and thus T-cell cytokine transcription. As steroid-sparing agents they avoid skin atrophy — useful on the face and skin folds where TCS side effects are worst.
crisaborole + PDE4 → ↑intracellular cAMP — via ↓TNF / IL-2 / IFN-γ in keratinocytes + T cells. Crisaborole inhibits phosphodiesterase-4 (PDE4), raising intracellular cAMP in immune cells and thereby suppressing pro-inflammatory cytokine production. This non-steroidal mechanism gives a mild anti-inflammatory effect suitable for maintenance in mild-to-moderate atopic dermatitis.
topical JAK inhibitor → JAK1/2 block → ↓STAT cytokine signaling — via ↓IFN + IL-4 + IL-13 keratinocyte response. Topical JAK inhibitors (e.g. ruxolitinib) block JAK1/2, cutting STAT-dependent signaling of the type-2 and itch cytokines (IL-4/IL-13, IL-31). They rapidly relieve itch and inflammation — a newer targeted topical option, carrying the class boxed-warning considerations of JAK inhibition.
sustained high-potency TCS → skin atrophy + HPA axis suppression — via tachyphylaxis + adverse effects motivate steroid-sparing. Prolonged high-potency topical steroids cause local skin atrophy, striae, and telangiectasia, and — especially over large or occluded areas — enough systemic absorption to suppress the HPA axis. These dose- and potency-dependent harms are why TCS are matched to site/severity and used with breaks or steroid-sparing agents.
Known Modulators
clobetasol (inhibitor) — GR — super-potent class I TCS (psoriasis short-burst + lichen)
hydrocortisone topical (inhibitor) — GR — low-potency class VII TCS (mild eczema, face/folds)